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Abstract 
Tumor recurrence after curative resection remains a major problem in patients 
with locally advanced colorectal cancer (CRC) treated with adjuvant chemotherapy. 
Genetic single nucleotide polymorphisms (SNPs) may serve as useful molecular markers 
to predict clinical outcomes in these patients and identify targets for future drug 
development. Recent in vitro and in vivo studies have demonstrated that the plastin genes, 
PLS3 and LCP1, are overexpressed in colon cancer cells and play an important role in 
tumor cell invasion, adhesion and migration. Hence, we hypothesized that functional 
genetic variations of plastin may direct effects on the progression and prognosis of 
locally advanced CRC. We tested whether functional tagging polymorphisms of PLS3 
and LCP1 predict time to tumor recurrence (TTR) in 732 patients (training set: 234; 
validation set: 498) with stage II/III CRC. The PLS3 rs11342 and LCP1 rs4941543 
polymorphisms were associated with a significantly increased risk for recurrence in the 
training set. PLS3 rs6643869 showed a consistent association with TTR in the training 
and validation set, when stratified by gender and tumor location. Female patients with the 
PLS3 rs6643869 AA genotype had the shortest median TTR compared to those with any 
G allele in the training set [1.7 vs. 9.4 years; HR 2.84(95% CI=1.32-6.1); p=0.005] and 
validation set [3.3 vs. 13.7 years; HR 2.07 (95%CI=1.09-3.91); p=0.021]. Our findings 
suggest that several SNPs of the PLS3 and LCP1 genes could serve as gender and/or 
stage-specific molecular predictors of tumor recurrence in stage II/III CRC patients as 
well as potential therapeutic targets.  
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Introduction 
Colorectal cancer (CRC) is the leading cause of death from gastrointestinal 
malignancy, with approximately 50,830 deaths expected in 2013 (1). Surgical resection 
affords the only chance for cure, and adjuvant chemotherapy is recommended for high-
risk stage II and all stage III tumors as it reduces risk of recurrence and prolongs disease-
free survival (2, 3). However, even with adjuvant chemotherapy, 20-30% of high-risk 
stage II and 50-65% of stage III patients relapse within 5 years. Disease recurrence and 
survival are related to tumor histology, grade and stage. Such conventional 
clinicopathological staging has served as the standard measure of prognosis for many 
years. We have yet to identify reliable molecular markers to predict tumor recurrence in 
patients with stage II-III disease who have received adjuvant chemotherapy.  
While a number of genes have been implicated in colorectal cancer metastasis, the 
precise mechanisms directing the migration and invasion of tumor cells into specific 
organs remain elusive. Modulation of the actin cytoskeleton is critical for tumor cell 
migration and invasion (4), and changes in the actin cytoskeleton are accomplished by a 
variety of actin-binding proteins, such as plastins (4, 5). Moreover, increasing evidence 
suggests that overexpression of plastins in cultured epithelial cells can increase cell 
motility (6). Therefore, plastins may not only be a potential biomarker but also serve as a 
valuable target for inhibiting tumor cell invasion and metastasis.  
The human plastin family is comprised of three protein isoforms: T-plastin 
(PLS3), L-plastin (LCP1) and I-plastin. I-plastin is specifically expressed in the small 
intestine and kidney. The cell-type-specific expression of the other isoforms (PLS3 and 
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LCP1) is regulated under physiological conditions. However, ectopic expression of 
plastins in malignant cells has been observed in many studies (7, 8). PLS3 and LCP1, 
which have 80% amino acid homology, also share the unique property of cross-linking 
actin filaments into tight bundles. Although PLS3 and LCP1 are related in structure and 
function, they are encoded by two distinct genes located on chromosomes X and 13, 
respectively (9), and possess other unique features. Specifically, PLS3 is expressed in a 
wide variety of cells except for hematopoietic cells. Most neoplastic cells derived from 
solid tumors also express PLS3. Conversely, LCP1 is expressed in most human cancer 
and hematopoietic cell lines (7). PLS3 up-regulation by the lamina A filament protein has 
been correlated with increased invasiveness in CRC (10), and LCP1 overexpression plays 
a significant role in proliferation and invasion in colon cancer cell lines (11). 
Furthermore, LCP1 has been proposed to mediate cell adhesion and motility by binding 
actin (9, 12). However, little is known about the role of PLS3 and LCP1 in colorectal 
tumor metastasis.  
Previously, data from our group and others have shown that certain genetic 
polymorphisms may predict clinical outcomes in colon cancer patients treated with 
adjuvant chemotherapy (13, 14). These common single nucleotide variations may alter 
gene transcription, translation or splicing, thereby causing different tumor recurrence and 
chemoresistance patterns. Since plastin genes play an important role in tumor cell 
invasion, adhesion and migration, functional variations in these genes may translate into 
direct effects on prognosis in patients with locally advanced colon cancer. To test this 
hypothesis, we performed a comprehensive study using both a training and validation set 
to evaluate associations between 6 functional PLS3 (4) and LCP1 (2) polymorphisms 
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with clinical outcomes, including TTR, in colon cancer patients treated with adjuvant 
chemotherapy. Lastly, we explored whether PLS3 and LCP1 polymorphisms 
demonstrated gender or stage-specific differences and if such differences correlated with 
clinical outcomes.  
 
Materials and Methods 
Eligible Patients 
A total of 234 patients with stage III and high-risk stage II colon cancer were 
included in this study as the training set (USC cohort) (Table 1). High risk stage II 
disease was defined by the presence of any of the following: T4 tumor, positive surgical 
margins, grade 3 or 4 histology in the absence of MSI-high status, perforation, 
obstruction, lymphovascular or perineural invasion, or less than 12 lymph nodes sampled 
at time of surgical resection (15). All patients were treated with 5-FU-based adjuvant 
chemotherapy at the Norris Comprehensive Cancer Center/University of Southern 
California (NCCC/USC) or the Los Angeles County/USC-Medical Center 
(LAC/USCMC) from 1987 to 2007. For the validation set (Table 1), a total of 498 
patients with histologically confirmed stage II (both high risk and low risk tumors) and 
stage III colon cancer treated at the Division of Clinical Oncology, Department of 
Medicine, Medical University of Graz (MUG) from 2000 to 2009 were included. All 
patients were treated with a 5-fluorouracil (5-FU)-based regimen. All patients were 
included in the colon cancer surveillance program of NCCC/USC, LAC/USCMC, or 
MUG, providing the following information: history and physical examination and 
carcinoembryonic antigen (CEA) levels every 3 months for 3 years and every 6 months at 
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years 4 and 5 after surgery; colonoscopy at year 1 and thereafter every 3–5 years; and 
computed tomography scans of chest and abdomen every 6 months for the first 3 years. 
Patient data were collected retrospectively through chart review. Whole blood was 
collected at the time of diagnosis and stored at −80°C. The study was approved by the 
Institutional Review Boards of MUG and USC, and all study participants signed 
informed consent for the analysis of molecular correlates.  
 
Candidate Polymorphisms  
Stringent pre-defined criteria were used to select candidate single nucleotide   
polymorphisms (SNPs) and included: (a) polymorphisms which could alter gene function 
in a biologically relevant manner (as predicted by the Functional-Single-Nucleotide-
Polymorphism (F-SNP) database) (16, 17); (b) a minor allele frequency ≥10% in 
Caucasians (with relative allelic frequencies of polymorphisms in different ethnicities 
obtained from the genetics section in the Ensembl Genome Browser: 
http://uswest.ensembl.org/index.html). This study focused on testing the potentially 
functional genetic variants located at the 5’UTR, 3’UTR, or coding region, as well as 
tagging SNPs. (Supplementary Table 1).  
 
Genotyping  
Genomic DNA was extracted from peripheral blood using the QIAmp-kit 
(Qiagen) and according to the manufacturer's instructions (www.qiagen.com). For the 
USC cohort, the candidate polymorphisms were tested using PCR-based direct DNA 
sequence analysis. Briefly, forward and reverse primers were used for PCR amplification. 
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PCR fragments were sequenced on an ABI 3100A Capillary Genetic Analyzer (Applied 
Biosystems) and analyzed in either sense or antisense directions for the presence of the 
polymorphism. DNA sequence analyses were performed using the ABI Sequencing 
Scanner v1.0 (Applied Biosystems). The investigator analyzing the germline 
polymorphisms was blinded to the clinical dataset. For the MUG cohort, genotypes were 
centrally determined by a 5'-exonuclease assay (TaqMan) at the Medical University of 
Graz. Primer and probe sets were designed and manufactured using Applied Biosystems 
‘Assay-by-Design’ custom service (Applera, Austria). General TaqMan reaction 
conditions were according to the manufacturer of the assays. End-point fluorescence was 
measured in a Lambda Fluoro 320 plus plate reader (MWG Biotech AG, Germany) using 
excitation/emission filters of 485/530 nm and 530/572 nm, respectively. In the plot, 
genotype groups were identified as separate and distinguishable clusters. To ensure 
methodological consistency and quality control, genotype determination was repeated in 
at least 96 randomly selected samples. 
 
Statistical Analysis 
The primary endpoint of this study was time to tumor recurrence (TTR), which 
was computed from the date of diagnosis of colon cancer to the date of the first 
documented tumor recurrence. If tumor recurrence was not observed, TTR was censored 
at the time of death or at the last follow-up. Deviation from Hardy-Weinberg equilibrium 
for allelic distributions of PLS3 and LCP1 SNPs were tested using a 1-degree-freedom 
χ2. The relationships between PLS3 and LCP1 SNPs and baseline patient and tumor 
characteristics were examined using χ2 or Fisher’s exact test whenever appropriate. The 
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associations between PLS3 and LCP1 SNPs and TTR were assessed using Kaplan-Meier 
curves and log-rank tests in the univariate analysis, and Cox regression models adjusting 
for stage and type of adjuvant therapy, stratified by race in the multivariate analysis. As 
the PLS3 gene is located on X chromosome, the analyses for all PLS3 SNPs were 
conducted separately by gender. We tested the hypothesis that plastin polymorphisms 
predict time to recurrence in patients with stage II or III colon cancer in our USC 
institutional cohort first. These findings were then validated in an independent cohort. 
Concordance probability estimates (CPE) for the Cox proportional hazards model were 
calculated to evaluate the incremental contribution in discrimination provided by the 
PLS3 and LCP1 SNPs over the baseline prognostic factors in both cohorts (18). 
SAS 9.3 (SAS Institute, Cary, NC, USA) and R package ‘CPE’ were used to 
perform all the analyses. All tests were 2-sided at a significance level of 0.05. 
 
Results 
The baseline characteristics of the training set and validation set patients included 
in this analysis are summarized in Table 1. All genotype frequencies for plastin 
polymorphisms analyzed were within Hardy-Weinberg equilibrium (HWE) (p>0.05). 
Training Set 
A total of 234 USC patients with stage II and III CRC were included in this 
analysis as the training set (14). All patients were diagnosed with stage III and high risk 
stage II CRC during the years of 1987 and 2007. The group consisted of 107 women 
(46%) and 127 men (54%), with a median age of 59 years (range 22–87 years). The 
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median follow-up was 4.4 years (range 0.4-16.8 years). Of the 234 CRC patients, ninety 
(38.5%) patients showed tumor recurrence, with a stage III and high-risk stage II 
dependent 3-year recurrence probability of 0.45 ± 0.047 and 0.21 ± 0.043, respectively. 
The median TTR was 7.1 years (95% CI 4.9-16.8+ years), and forty-four (19%) of the 
234 patients died. The median OS for this cohort has not yet been reached. Patients with 
stage III disease were more likely to present with recurrence, compared with patients with 
high risk stage II disease (log-rank p<0.001). We did not observe any significant 
associations between other demographic and clinicopathologic variables and TTR. In the 
USC cohort, plastin polymorphisms were not significantly associated with age, clinical 
(type of chemotherapy administered) or pathological characteristics (tumor stage, grade 
or lymph node status) (p>0.05). 
Validation Set 
In order to validate our results, we performed an analysis of the polymorphisms, 
PLS3 rs6643869 and LCP1 rs4941543, in an independent Austrian cohort of 498 patients 
with stage II and III CRC. Baseline patient characteristics, tumor biological factors and 
therapeutic modalities are shown in Table 1. The median age at time of diagnosis was 66 
years (range 27-95 years). The median follow-up time was 64 months (range 1-186 
months). The median OS of this cohort was 15.3 years (95% CI 9.7-15.5+ years).  
 
Single Nucleotide Polymorphism (SNP) Analysis 
Training Set 
Genotyping of PLS3 rs6643869 and LCP1 rs4941543 was successful in 180 
(77%) of the 234 patients. In the remaining 54 (23%) cases, there was limited quantity 
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and/or quality of extracted genomic DNA. As the PLS3 gene is located on the X 
chromosome, data were analyzed separately for men and women for the PLS3 
polymorphism. In univariate analysis, PLS3 rs6643869 and LCP1 rs4941543 were 
significantly associated with time to tumor recurrence (TTR). Female patients with the 
PLS3 rs6643869 A/A genotype had a shorter median TTR of 1.7 years (95% CI 0.7-5.9+ 
years) compared to those with the A/G or G/G genotypes, who had a median TTR of 9.4 
years (95% CI 5.4-12.2+ years) (HR=2.84, 95% CI 1.32-6.10; p=0.005, log-rank test) 
(Figure 1, top panel; Table 2). We further analyzed female patients with PLS3 rs6643869 
by tumor location. Both sides (right and left) have similar results (Supplementary Figure 
1).  All patients with the LCP1 rs4941543 C/C genotype had a longer median TTR of 
10.7 years (95% CI 5.7-16.8+ years) compared to those with the C/T and T/T genotypes, 
who had a median TTR of 4.9 years (95% CI 2.0-9.0+ years) (HR=1.83, 95% CI 1.01-
3.30; p=0.040, log-rank test) (Figure 1, bottom panel; Supplementary Table 2). In 
addition, male patients with the LCP1 rs11342 T allele had a longer median TTR of 7.1 
years (95% CI 4.9-11.4+ years), relative to men with the G/G genotype who had a 
median TTR 2.3 years, (95% CI 1.5-6.8+ years) (HR=0.51, 95% CI 0.25-1.04; p=0.042) 
in univariate analysis (Supplementary Figure 2, Table 2). 
The multivariate model for the USC cohort was adjusted for stage and type of 
chemotherapy as covariates and stratified by race and gender. The A/A genotype (n=14) 
of PLS3 rs6643869 demonstrated a non-significant trend towards decreased TTR 
(HR=2.26, 95% CI 0.97-5.31; adjusted p=0.06) compared with patients with the A/G or 
G/G genotypes (n = 68) in female patients (Table 2). CPE was 0.728 (standard error (SE): 
0.039) and 0.741 (SE: 0.037) for the multivariate model including baseline patient 
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prognostic factors only (baseline model), and adding PLS3 rs6643869 into the model 
among female patients, respectively. LCP1 rs4941543 was not associated with TTR in 
multivariate analysis (adjusted p=0.11) in any population. However, amongst female 
patients, those with the C/C genotype had a lower risk of recurrence than carriers of the T 
allele (HR=2.95, 95% CI 1.10-7.90; adjusted p=0.031). CPE was 0.769 (SE: 0.034) for 
LCP1 rs4941543-added multivariate model and 0.744 (SE: 0.034) for the baseline model. 
There were no statistically significant differences between the PLS3 rs6643869, LCP1 
rs4941543 and LCP1 rs11432 polymorphisms and TTR in male patients (Supplementary 
Figure 3; Table 2). These data suggest that the PLS3 rs6643869 and LCP1 rs4941543 
polymorphisms may serve as gender-based prognostic factors. We did not observe 
statistically significant associations between the other tested genes with regards to time to 
disease relapse (Supplementary Table 3).  
 
Validation Set 
In the overall population analysis, the PLS3 rs6643869 and LCP1 rs4941543 
polymorphisms were not associated with TTR in the validation set. However, when 
patients were stratified by gender, tumor location and stage, the PLS3 rs6643869 and 
LCP1 rs4941543 polymorphisms demonstrated the following significant relationships:  
1) In right-sided CRC, female patients with any G allele of PLS3 rs6643869 had an 
increased TTR (13.7+ years) compared to the G/A and A/A genotypes (3.3 years) (Figure 
2, top panel) in both univariate (HR=2.07, 95% CI 1.09-3.91; p=0.021) and multivariate 
analyses (HR=2.41, 95% CI 1.22-4.76; p=0.011) (Table 3, top right panel). CPE was 
0.639 (SE: 0.037) and 0.672 (SE: 0.034) for the baseline multivariate model and PLS3 
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rs6643869-added model, respectively. In men, PLS3 rs6643869 was not significantly 
associated with TTR (Table 3, bottom left panel). These data suggest that the PLS3 
rs6643869 polymorphism is a positive prognostic indicator whose influence depends 
upon both gender and tumor location. 
2) Women with the LCP1 rs4941543 C/C genotype had a shorter TTR (10 years, 95% CI 
6.9-14.1+ years) compared to those with any T allele in univariate analysis (TTR 12.2+ 
years; HR=0.53, 95% CI 0.29-0.97; p=0.035) (Figure 2, bottom panel) and remained 
significantly associated in multivariate analysis (HR=0.53, 95% CI 0.29-0.97; p=0.039) 
(Table 3, bottom panel). CPE was 0.650 (SE: 0.029) and 0.667 (SE: 0.028) for the 
baseline multivariate and LCP1 rs4941543-added model, respectively. These data are in 
contradiction to that found in our USC training cohort, which showed the C/C genotype 
to correlate with decreased risk of recurrence.  
3) In stage III CRC, female patients with the LCP1 rs4941543 C/C genotype had a 
significantly decreased TTR (4.1 years) than carriers of the T allele in univariate analysis 
(10.6 years) (HR=0.47, 95% CI 0.23-0.96, p=0.031), with a similar but non-significant 
trend in multivariate analysis (HR=0.49, 95% CI 0.24-1.01; p=0.052) (Table 4). These 
data support the role of LCP1 rs4941543 as a prognosticator based on gender and tumor 
stage.  
Discussion 
In this study, we demonstrated that germline polymorphisms within the PLS3 and 
LCP1 genes are significantly associated with time to tumor recurrence in patients with 
locally advanced colon cancer treated with adjuvant chemotherapy. Moreover, when 
stratified by gender, the PLS3 rs6643869 and LCP1 rs4941543 polymorphisms correlate 
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with TTR in women. The correlation between clinical outcomes and PLS3 rs6643869 
was validated in an independent Austrian cohort. To our knowledge, this is the first report 
suggesting a relationship between PLS3 and LCP1 polymorphisms and clinical outcomes 
in stage II/III colon cancer patients that is dependent upon gender, tumor location, and 
stage. These findings suggest that plastins may serve as a useful prognostic biomarker 
and warrant further investigation.  
Our study identified several SNPs in the PLS3 and LCP1 genes that may play a 
significant role in predicting outcomes of stage II/III colon cancer patients. Patients with 
the PLS3 rs6643869 polymorphism A/A genotype in the intron region of the PLS3 gene 
had a significantly higher risk of tumor recurrence compared with patients carrying at 
least one G allele in both the training and validation sets. Patients carrying the LCP1 
rs4941543 polymorphism C/C genotype in the exon region of the LCP1 gene had a 
significantly lower risk of tumor recurrence compared with patients possessing either C/T 
or T/T in our training set. However, our validation set showed an opposite relationship 
between the C/C genotype and outcomes. This discrepancy could be attributed to two 
reasons. First, differences in ethnicity between the two populations may translate into 
contrasting pharmacogenomic interactions or activation of alternate pathways which 
affect tumor cell biology and behavior. Secondly, whereas the training set included only 
high risk stage II patients, the validation cohort included both high and low risk stage II 
patients (as we could not discern high or low risk status from the available clinical data). 
Low risk stage II patients may have a longer TTR and are more likely to live long enough 
to develop a recurrence.  
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The molecular mechanisms by which plastin polymorphisms affect tumor 
behavior and recurrence are under investigation. Modulations of transcription, 
interconnected stem cell pathways, and treatment-related factors have all been implicated. 
With regards to transcription, we know that the PLS3 rs6643869 polymorphism is located 
at intron 2 of PLS3 gene, and the SNP functional prediction tool (F-SNP) has shown that 
a single nucleotide change from A to G may alter transcription factor binding of this 
gene. For example, PLS3 rs6643869 containing the G allele but not the A allele binds 
two transcription factors, Tst-1 and HSF, which may affect subsequent transcriptional 
activity in a process known as intron-mediated enhancement. With regards to the LCP1 
rs4941543 polymorphism located at exon 18, a missense mutation from C to T renders an 
amino acid change from lysine (K) to glutamine (E), which may lead to potential 
functional alterations. Moreover, our findings suggest that PLS3 rs6643869 and LCP1 
rs4941543 are gender-specific markers, which may imply further hormonal interactions. 
The fact that PLS3 maps to X.q23 may partly account for its gender-specific effect, but 
additional studies are needed to better elucidate the mechanisms underlying these 
associations. 
Once deranged transcription has occurred, plastins may then mediate colon cancer 
metastasis through two distinct mechanisms. The first involves the Epithelial-
Mesenchymal Transition (EMT) which is critical for cancer development and metastasis 
(19, 20). A key effector of this transition is E-cadherin, and E-cadherin expression levels 
have reliably demonstrated an inverse correlation with tumor invasiveness. It follows that 
loss of E-cadherin expression occurs at sites of EMT during tumor progression (21, 22). 
Therefore, one possibility is that overexpressed PLS3 and LCP1 in colon cancer cells 
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lead to loss of E-cadherin (10, 11) and thereby promotes β-catenin release through the 
Wnt-signaling pathway (23, 24), facilitating passage through the EMT. Alternatively, 
plastin overexpression may enhance cell motility by modifying the actin cytoskeleton 
and, in doing so, increase metastatic potential.  
Studies using CRC cell lines have shown a promising link between PLS3, the 
epithelial mesenchymal transition, and tumor metastasis. Willis and colleagues (10) 
showed that lamina A, a putative colon stem cell biomarker, can induce PLS3 
upregulation, which in turn leads to E-cadherin downregulation and increased tumor 
invasiveness.  Furthermore, a recent study led by Yokobori reported that PLS3 itself may 
be a novel circulating tumor cell (CTC) marker expressed during the epithelial 
mesenchymal transition (EMT), and the detection of PLS3-positive CTCs was found to 
be an independent prognostic factor in metastatic CRC patients (25).  Our study showed 
that PLS3 plasma concentration was significantly higher in CRC patients compared to 
control patients with no evident disease (NED) (Supplementary Figure 4), which is 
consistent with previous studies, and suggests that PLS3 expression may serve as a 
surrogate for tumor invasiveness in stage II/III CRC. 
Other studies have similarly demonstrated a connection between LCP1, E-
cadherin mediated tumor spread, and poor prognosis in colon cancer. Elevated LCP1 
levels in cancer cell lines and solid tumors have been correlated with increased migration, 
invasion and metastatic potential (12, 26, 27). In CRC, several independent studies have 
confirmed that L-plastin protein overexpression is also a marker for aggressive disease 
and poor prognosis (28, 29). Foran et al. (11) showed that CRC cell lines overexpressing 
LCP1 acquire invasiveness through E-cadherin downregulation, which induces 
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dedifferentiation, invasion and metastasis. Furthermore, others (29, 30) have shown that 
LCP1 correlates with tumor protein expression and CRC progression using 
immunohistochemical analysis and ELISA, which is consistent with our results in the 
USC cohort. Our data showed that LCP1 plasma concentration was much higher in CRC 
patients than NED control patients. Moreover, LCP1 was higher in stage III than stage II 
patients, suggesting that LCP1 expression may be related to lymph node metastasis 
(Supplementary Figure 3). 
In addition to affecting the intrinsic invasiveness of tumor cells, PLS3 has been 
implicated in modulating chemotherapeutic efficacy. Specifically, enhanced PLS3 
expression has been associated with both chemotherapy and radiation resistance in cancer 
cells (31, 32). Hisano et al. reported that PLS3 downregulation led to increased 
sensitivity to cisplatin in platinum-resistant cell lines. In our future studies, we will focus 
on the correlation between plastin expression levels and the presence of LCP1 or PLS3 
polymorphisms. The PLS3 rs6643869 and LCP1 rs4941543 polymorphisms, in 
particular, may alter gene function/expression, thereby increasing PLS3 and LCP1 levels 
and promoting Wnt signaling through the E-cadherin/ß-catenin complex, ultimately 
resulting in CRC recurrence and progression.  
In summary, this study provides the first evidence that germline genetic variants 
of the PLS3 and LCP1 genes predict tumor recurrence and time to disease relapse in a 
gender-and stage-specific manner. The PLS3 rs6643869 SNP retained a significant 
correlation with outcomes after adjusting for multiple variables and has now been 
confirmed in a validated cohort.  Taken together, our data strengthen the role of plastin 
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proteins in locally advanced CRC and may aid in the selection of patients who would 
benefit from plastin-targeted treatments in the future.    
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Table 1. Colorectal cancer baseline patient characteristics 
 
 Training set (USC cohort) Validation set (Austrian cohort) P value*
 n % n % 
Age, years  
<55 86 36.75 87 17.47 
55-64 82 35.04 138 27.71 
≥65 66 28.21 273 54.82 <0.001
   
Sex   
Female 107 45.72 230 46.18 
Male 127 54.28 268 53.82 0.91
T   
T1 2 0.85 10 2.01 
T2 14 5.98 22 4.42 
T3 187 79.91 358 71.89 <0.001
T4 27 11.54 108 21.69 
Tx 4 1.72 0  
N   
Negative 105 44.87 192 38.55 
N1 72 30.77 195 39.16 
N2 57 24.36 111 22.29 0.085
Grade   
Well 11 2.18 25 5.02 
Moderate 151 64.53 326 65.46 
Poor/undifferentiated 54 23.08 145 29.12 0.51
Missing 18 10.21 2 0.40 
Stage   
II 105 44.87 192 38.55 
III 129 55.13 306 61.45 0.10
N of resected lymph nodes  
≤12 70 29.91 72 14.46 
>12 145 61.97 426 85.54 <0.001
Missing 19 8.12 0 0 
Tumor side   
Left 110 47.01 188 37.75 
Right 115 49.15 310 62.25 0.005
Left and right 4 1.71 0  
Missing 5 2.13 0  
Adjuvant treatment   
5-FU 151 64.53 171 34.41 
5-FU/LV/Oxaliplatin 60 25.64 326 65.59 <0.001
5-FU/LV/Irinotecan 23 9.83 0 0 
Ethnicity   
Asian 34 14.53 0 0 
African American 15 6.41 0 0 
Caucasian 123 52.56 498 100 <0.001
Hispanic 62 26.5 0 0 
*Based on χ2 test 
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Table 2. PLS3 and LCP1 polymorphisms and outcome in patients with stage II or III colon cancer by sex (Training set) 
 Males  Females 
 N Median TTR, 
y (95% CI) 
Prob ± SE* of 
3-y recurrence 
HR (95% CI) 
Univariate 
HR (95% CI) 
Multivariate 
 N Median TTR, 
y (95% CI) 
Prob ± SE* of 
3-y recurrence 
HR (95% CI) 
Univariate 
HR (95% CI) 
Multivariate 
PLS3 
rs6643869 
           
 G/G 66 7.1 (3.5, 11.4+) 0.33 ± 0.07 1 (Reference) 1 (Reference)  35 12.2+ (4.9, 12.2+) 0.29 ± 0.08 1 (Reference) 1 (Reference) 
 G/A 27 5.2 (1.7, 10.7+) 0.36 ± 0.10 1.38 (0.69, 2.75) 1.48 (0.71, 3.08)  33 9.4 (5.4, 9.4+) 0.20 ± 0.08 0.89 (0.37, 2.14) 0.75 (0.30, 1.92) 
 A/A    0.35 0.30  14 1.7 (0.7, 5.9+) 0.67 ± 0.13 2.69 (1.14, 6.35) 1.96 (0.75, 5.13) 
P†          0.018 0.15 
 G/G or G/A       68 9.4 (5.4, 12.2+) 0.25 ± 0.06 1 (Reference) 1 (Reference) 
 A/A       14 1.7 (0.7, 5.9+) 0.67 ± 0.13 2.84 (1.32, 6.10) 2.26 (0.97, 5.31) 
P†          0.005 0.060 
LCP rs11342            
 G/G 33 2.3 (1.5, 6.8+) 0.52 ± 0.11 1 (Reference) 1 (Reference)  23 10.3+ 0.23 ± 0.09 1 (Reference) 1 (Reference) 
 G/T 42 10.7 (5.2, 11.4+) 0.17 ± 0.06 0.39 (0.17, 0.89) 0.36 (0.14, 0.92)  44 5.4 (1.8, 9.4+) 0.40 ± 0.08 2.27 (0.86, 6.03) 1.53 (0.50, 4.63) 
 T/T 21 3.9 (1.4, 10.7+) 0.41 ± 0.11 0.78 (0.34, 1.83) 0.71 (0.29, 1.73)  17 12.2+ (2.8, 12.2+) 0.21 ± 0.11 1.00 (0.27, 3.71) 0.68 (0.16, 2.85) 
P†    0.037 0.096     0.10 0.31 
 G/T, T/T 63 7.1 (4.9, 11.4+) 0.25 ± 0.06 0.51 (0.25, 1.04) 0.50 (0.23, 1.10)  61 5.7 (2.8, 16.8+) 0.35 ± 0.07 1.89 (0.72, 4.93) 1.29 (0.43, 3.85) 
P†    0.042 0.085     0.19 0.65 
LCP 
rs4941543 
           
 C/C 75 10.7 (5.2, 11.4+) 0.30 ± 0.06 1 (Reference) 1 (Reference)  66 9.4 (5.4, 16.8+) 0.27 ± 0.06 1 (Reference) 1 (Reference) 
 C/T‡ 14 4.9 (1.0, 7.1+) 0.35 ± 0.13 1.75 (0.77, 3.97) 1.60 (0.64, 3.97)  15 2.4 (0.7, 9.0+) 0.52 ± 0.14 1.91 (0.81, 4.52) 2.95 (1.10, 7.90) 
 T/T‡ 1      0     
P†    0.17 0.32     0.13 0.031 
* Greenwood SE. 
+ Estimates were not reached. 
†Based on log-rank test in the univariate analysis and based on Wald test within multivariate Cox proportional hazards model adjusting for stage and type of adjuvant therapy and 
stratified by race. 
‡In the dominant model. 
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Table 3. Associations between Plastin polymorphisms and disease-free survival in Austrian female patients with stage II or III colon cancer by tumor site and gender 
 (validation set) 
 
* Greenwood SE. 
†Based on log-rank test in the univariate analysis and based on Wald test within multivariate Cox proportional hazards model adjusting for age, stage, and adjuvant therapy. 
+ Estimates were not reached. ‡In the dominant model. 
 
 Left Colon  Right Colon 
 N Median TTR, 
y (95% CI) 
Probability 
± SE* of 
3-year 
recurrence 
HR (95% CI) 
in univariate 
analysis 
HR (95% CI)  
in multivariate 
analysis 
 N Median TTR, 
y (95% CI) 
Probability 
± SE* of 
3-year 
recurrence 
HR (95% CI) 
in univariate 
analysis 
HR (95% CI)  
in multivariate 
analysis 
PLS3 
rs6643869 
           
 G/G 27 10.8+ (0.9, 10.8+) 0.36 ± 0.10 1 (Reference) 1 (Reference)  52 13.7+ (4.6, 13.7+) 0.25 ± 0.07 1 (Reference) 1 (Reference) 
 G/A 41 10.6+ (3.5, 10.6+) 0.31 ± 0.08 0.84 (0.37, 1.90) 0.67 (0.29, 1.58)  58 13.2+ 0.28 ± 0.06 0.93 (0.45, 1.90) 0.99 (0.47, 2.06) 
 A/A 12 11.6+ (1.7, 11.6+) 0.11 ± 0.10 0.20 (0.03, 1.53) 0.23 (0.03, 1.79)  25 3.3 (1.4, 15.0+) 0.46 ± 0.10 1.98 (0.94, 4.17) 2.40 (1.09, 5.27) 
P†    0.23 0.31     0.068 0.040 
            
 G 68 10.8+ (3.7, 10.8+) 0.33 ± 0.06 1 (Reference) 1 (Reference)  110 13.7+ 0.26 ± 0.05 1 (Reference) 1 (Reference) 
 A/A 12 11.6+ (1.7, 11.6+) 0.11 ± 0.10 0.22 (0.03, 1.61) 0.29 (0.04, 2.15)  25 3.3 (1.4, 15.0+) 0.46 ± 0.10 2.07 (1.09, 3.91) 2.41 (1.22, 4.76) 
P†    0.099 0.22     0.021 0.011 
LCP1 
rs4941543 
           
 C/C 59 11.6+ (2.3, 11.6+) 0.37 ± 0.07 1 (Reference) 1 (Reference)  106 10.0 (6.9, 14.1+) 0.33 ± 0.05 1 (Reference) 1 (Reference) 
 C/T‡ 23 10.6+ 0.17 ± 0.08 0.47 (0.18, 1.24) 0.42 (0.16, 1.15)  31 12.2+ 0.23 ± 0.08 0.58 (0.27, 1.24) 0.59 (0.27, 1.28) 
 T/T‡ 1      2     
P†    0.11 0.092     0.15 0.18 
 Male  Female 
 N Median TTR, 
y (95% CI) 
Probability 
± SE* of 
3-year 
recurrence 
HR (95% CI) 
in univariate 
analysis 
HR (95% CI)  
in multivariate 
analysis 
 N Median TTR, 
y (95% CI) 
Probability 
± SE* of 
3-year 
recurrence 
HR (95% CI) 
in univariate 
analysis 
HR (95% CI)  
in multivariate 
analysis 
PLS3 
rs6643869 
           
 G/G 139 14.4 (14.4, 14.5+) 0.27 ± 0.04 1 (Reference) 1 (Reference)  79 13.7+ (6.9, 13.7+) 0.29 ± 0.06 1 (Reference) 1 (Reference) 
 G/A 100 12.0+ (4.0, 12.0+) 0.31 ± 0.05 1.36 (0.85, 2.19) 1.42 (0.88, 2.30)  99 13.2+ 0.29 ± 0.05 0.91 (0.53, 1.55) 0.88 (0.51, 1.52) 
 A/A       37 10.0 (2.1, 15.0+) 0.36 ± 0.08 1.24 (0.65, 2.37) 1.43 (0.73, 2.80) 
P†    0.19 0.15     0.61 0.33 
LCP1 
rs4941543 
           
 C/C 196 14.4 (14.4, 15.0) 0.28 ± 0.03 1 (Reference) 1 (Reference)  165 10.0 (6.9, 14.1+) 0.34 ± 0.04 1 (Reference) 1 (Reference) 
 C/T‡ 58 8.6 (3.9, 11.4+) 0.32 ± 0.07 1.16 (0.69, 1.95) 1.26 (0.74, 2.13)  54 12.2+ 0.21 ± 0.06 0.53 (0.29, 0.97) 0.53 (0.29, 0.97) 
 T/T‡ 4      3     
P†    0.58 0.39     0.035 0.039 
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Table 4. Associations between Plastin polymorphisms and disease-free survival in Austrian female patients with stage II or III colon cancer by stage (Validation set) 
 Stage II  Stage III 
 N Median TTR, 
y (95% CI) 
Probability 
± SE* of 
3-year 
recurrence 
HR (95% CI) 
in univariate 
analysis 
HR (95% CI)  
in multivariate 
analysis 
 N Median TTR, 
y (95% CI) 
Probability 
± SE* of 
3-year 
recurrence 
HR (95% CI) 
in univariate 
analysis 
HR (95% CI)  
in multivariate 
analysis 
PLS3 
rs6643869 
           
 G/G 28 12.2+ (4.6, 
12.2+) 
0.18 ± 0.08 1 (Reference) 1 (Reference)  51 13.7+ (2.9, 13.7+) 0.35 ± 0.07 1 (Reference) 1 (Reference) 
 G/A 37 13.2+ 0.10 ± 0.06 0.42 (0.12, 1.49) 0.40 (0.11, 1.41)  62 10.6+ (2.3, 10.6+) 0.39 ± 0.06 1.09 (0.60, 1.99) 1.03 (0.56, 1.89) 
 A/A 19 10.0 (3.3, 
15.0+) 
0.17 ± 0.09 1.03 (0.32, 3.26) 0.90 (0.28, 2.91)  18 2.1 (1.1, 11.6+) 0.58 ± 0.13 1.52 (0.68, 3.39) 1.43 (0.63, 3.24) 
P†    0.29 0.31     0.57 0.66 
            
 G 65 13.2+ 0.14 ± 0.05 1 (Reference) 1 (Reference)  113 13.7+ (3.5, 13.7+) 0.37 ± 0.05 1 (Reference) 1 (Reference) 
 A/A 19 10.0 (3.3, 
15.0+) 
0.17 ± 0.09 1.59 (0.57, 4.45) 1.47 (0.52, 4.17)  18 2.1 (1.1, 11.6+) 0.58 ± 0.13 1.44 (0.70, 2.97) 1.41 (0.68, 2.93) 
P†    0.36 0.47     0.31 0.36 
LCP1 
rs4941543 
           
 C/C 64 14.1+ (8.5, 
14.1+) 
0.15 ± 0.05 1 (Reference) 1 (Reference)  101 4.1 (1.8, 13.7+) 0.46 ± 0.05 1 (Reference) 1 (Reference) 
 C/T‡ 23 12.2+ 0.15 ± 0.08 0.75 (0.24, 2.31) 0.64 (0.21, 1.98)  31 10.6+ 0.25 ± 0.08 0.47 (0.23, 0.96) 0.49 (0.24, 1.01) 
 T/T‡ 1      2     
P†    0.61 0.44     0.031 0.052
 
* Greenwood SE. 
+ Estimates were not reached. 
†Based on log-rank test in the univariate analysis and based on Wald test within multivariate Cox proportional hazards model adjusting for age, stage, and adjuvant therapy. 
‡In the dominant model. 
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Figure legends. 
Figure 1. Time-to-tumor recurrence (TTR) by PLS3rs6643869 and LCP14941543 in USC cohort (Training set) stage 
II/III CRC patients treated with 5-fluorouracil (5-FU)-based chemotherapy. 
Figure 2. Time-to-tumor recurrence (TTR) by PLS3rs6643869 and LCP14941543 in Austrian cohort (Validation set) 
stage II/III CRC patients treated with 5-fluorouracil (5-FU)-basedchemotherapy.  
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